Book contents
- The Lithium Handbook
- Reviews
- The Lithium Handbook
- Copyright page
- Contents
- Foreword
- Preface: How to Use This Handbook
- Introduction
- 1 The Efficacy Story
- 2 Renal Handling of Lithium
- 3 Clinical Pharmacokinetics
- 4 Lithium Initiation and Monitoring
- 5 Management of Routine Lithium Related Adverse Effects
- 6 Lithium Toxicity
- 7 Special Populations and Circumstances
- 8 Lithium Discontinuation
- Index
- References
8 - Lithium Discontinuation
Advantages of Gradual Tapering; Suicide Risk Following Discontinuation; Efficacy Upon Resumption
Published online by Cambridge University Press: 09 February 2024
Book contents
- The Lithium Handbook
- Reviews
- The Lithium Handbook
- Copyright page
- Contents
- Foreword
- Preface: How to Use This Handbook
- Introduction
- 1 The Efficacy Story
- 2 Renal Handling of Lithium
- 3 Clinical Pharmacokinetics
- 4 Lithium Initiation and Monitoring
- 5 Management of Routine Lithium Related Adverse Effects
- 6 Lithium Toxicity
- 7 Special Populations and Circumstances
- 8 Lithium Discontinuation
- Index
- References
Summary
There are numerous reasons for lithium discontinuation, some patient driven and others motivated by clinician concerns [1]. Focused and early attention to common adverse effects may forestall a certain proportion of somatic complaints leading to lithium refusal, but patients may also stop lithium due to the inconvenience of daily medication; diminished perceived need for lithium during periods of euthymia; a desire to remain in a hypomanic or even manic state (e.g. because they feel more creative or productive, or miss the elevated mood); comparative lack of efficacy for depressive episodes compared with the significant impact on mania; a wish not to be reminded of the illness itself; and not wanting their mood to be regulated by medication [2–4].
- Type
- Chapter
- Information
- The Lithium HandbookStahl's Handbooks, pp. 428 - 441Publisher: Cambridge University PressPrint publication year: 2023
References
Öhlund, L., Ott, M., Oja, S., et al. (2018). Reasons for lithium discontinuation in men and women with bipolar disorder: A retrospective cohort study. BMC Psychiatry, 18, 37–46.CrossRefGoogle ScholarPubMed
Van Putten, T. (1975). Why do patients with manic-depressive illness stop their lithium? Compr Psychiatry, 16, 179–183.CrossRefGoogle ScholarPubMed
Jamison, K. R., Gerner, R. H. and Goodwin, F. K. (1979). Patient and physician attitudes toward lithium: Relationship to compliance. Arch Gen Psychiatry, 36, 866–869.CrossRefGoogle ScholarPubMed
Vestergaard, P. and Amdisen, A. (1983). Patient attitudes towards lithium. Acta Psychiatr Scand, 67, 8–12.CrossRefGoogle ScholarPubMed
Kirkham, E., Skinner, J., Anderson, T., et al. (2014). One lithium level > 1.0 mmol/L causes an acute decline in eGFR: Findings from a retrospective analysis of a monitoring database. BMJ Open, 4, e006020.CrossRefGoogle ScholarPubMed
Clos, S., Rauchhaus, P., Severn, A., et al. (2015). Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: A population-based cohort study. Lancet Psychiatry, 2, 1075–1083.CrossRefGoogle Scholar
Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: An electronic health record study. Neuropsychopharmacology, 41, 1138–1143.CrossRefGoogle ScholarPubMed
Velosa, J., Delgado, A., Finger, E., et al. (2020). Risk of dementia in bipolar disorder and the interplay of lithium: A systematic review and meta-analyses. Acta Psychiatr Scand, 141, 510–521.CrossRefGoogle ScholarPubMed
Golic, M., Aiff, H., Attman, P. O., et al. (2021). Starting lithium in patients with compromised renal function – is it wise? J Psychopharmacol, 35, 190–197.CrossRefGoogle ScholarPubMed
Gerhard, T., Devanand, D. P., Huang, C., et al. (2015). Lithium treatment and risk for dementia in adults with bipolar disorder: Population-based cohort study. Br J Psychiatry, 207, 46–51.CrossRefGoogle ScholarPubMed
Flapper, M., van Melick, E., van Campen, J., et al. (2021). Tolerability of lithium: A naturalistic discontinuation study in older inpatients (≥ 60 years). Int J Geriatr Psychiatry, 36, 1231–1240.CrossRefGoogle ScholarPubMed
Rej, S., Yu, C., Shulman, K., et al. (2015). Medical comorbidity, acute medical care use in late-life bipolar disorder: A comparison of lithium, valproate, and other pharmacotherapies. Gen Hosp Psychiatry, 37, 528–532.CrossRefGoogle ScholarPubMed
Kinahan, J. C., NiChorcorain, A., Cunningham, S., et al. (2015). Diagnostic accuracy of tests for polyuria in lithium-treated patients. J Clin Psychopharmacol, 35, 434–441.CrossRefGoogle ScholarPubMed
Schoot, T. S., Molmans, T. H. J., Grootens, K. P., et al. (2020). Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. Eur Neuropsychopharmacol, 31, 16–32.CrossRefGoogle ScholarPubMed
Pattan, V., Singh, B., Abdelmoneim, S. S., et al. (2021). Lithium-induced hyperparathyroidism: An ill-defined territory. Psychopharmacol Bull, 51, 65–71.Google ScholarPubMed
Ketteler, M., Bover, J. and Mazzaferro, S. (2022). Treatment of secondary hyperparathyroidism in non-dialysis CKD: An appraisal 2022s. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfac236.CrossRefGoogle Scholar
Lerena, V. S., León, N. S., Sosa, S., et al. (2022). Lithium and endocrine dysfunction. Medicina (B Aires), 82, 130–137.Google ScholarPubMed
Brugada, J., Campuzano, O., Arbelo, E., et al. (2018). Present status of Brugada Syndrome: JACC state-of-the-art review. J Am Coll Cardiol, 72, 1046–1059.CrossRefGoogle ScholarPubMed
Ravi, V., Serafini, N. J., Pulipati, P., et al. (2020). Lithium-induced Brugada pattern: A case report and review of literature. Cureus, 12, e9351–e9537.Google ScholarPubMed
Faedda, G. L., Tondo, L., Baldessarini, R. J., et al. (1993). Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry, 50, 448–455.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L. and Viguera, A. C. (1999). Discontinuing lithium maintenance treatment in bipolar disorders: Risks and implications. Bipolar Disord, 1, 17–24.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L. and Hennen, J. (1999). Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry, 60, 77–84.Google ScholarPubMed
Koukopoulos, A., Reginaldi, D., Minnai, G., et al. (1995). The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol, 49, 127–147.Google Scholar
Maj, M., Pirozzi, R. and Magliano, L. (1995). Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors. Am J Psychiatry, 152, 1810–1811.Google ScholarPubMed
de Vries, C., van Bergen, A., Regeer, E. J., et al. (2013). The effectiveness of restarted lithium treatment after discontinuation: Reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disord, 15, 645–649.CrossRefGoogle ScholarPubMed
Holm, M., Tanskanen, A., Lahteenvuo, M., et al. (2022). Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder. Eur Neuropsychopharmacol, 61, 36–42.CrossRefGoogle ScholarPubMed
Wingård, L., Brandt, L., Bodén, R., et al. (2019). Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort study. Eur Neuropsychopharmacol, 29, 691–700.CrossRefGoogle ScholarPubMed
Öhlund, L., Ott, M., Bergqvist, M., et al. (2019). Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: Mirror-image study based on the LiSIE retrospective cohort. BJPsych Open, 5, e101–112.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L., Faedda, G. L., et al. (1996). Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry, 57, 441–448.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Tondo, L., Floris, G., et al. (1997). Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: A replication study. Am J Psychiatry, 154, 551–553.Google ScholarPubMed
Baldessarini, R. J., Pinna, M., Contu, M., et al. (2022). Risk factors for early recurrence after discontinuing lithium in bipolar disorder. Bipolar Disord, 24, 720–725.CrossRefGoogle ScholarPubMed
Lahteenvuo, M., Tanskanen, A., Taipale, H., et al. (2018). Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry, 75, 347–355.CrossRefGoogle Scholar
Kishi, T., Ikuta, T., Matsuda, Y., et al. (2021). Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: A systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry, 26, 4146–4157.CrossRefGoogle ScholarPubMed
Chengappa, K. N. R., Schwarzman, L. K., Hulihan, J. F., et al. (2006). Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry, 67, 1698–1706.CrossRefGoogle Scholar
Kushner, S. F., Khan, A., Lane, R., et al. (2006). Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord, 8, 15–27.CrossRefGoogle ScholarPubMed
Vasudev, A., Macritchie, K., Watson, S., et al. (2008). Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev, CD005171.CrossRefGoogle Scholar
Kishi, T., Ikuta, T., Matsuda, Y., et al. (2022). Pharmacological treatment for bipolar mania: A systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry, 27, 1136–1144.CrossRefGoogle Scholar
Pande, A. C., Crockatt, J. G., Janney, C. A., et al. (2000). Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord, 2, 249–255.CrossRefGoogle ScholarPubMed
Fullerton, C. A., Busch, A. B. and Frank, R. G. (2010). The rise and fall of gabapentin for bipolar disorder: A case study on off-label pharmaceutical diffusion. Medical Care, 48, 372–379.CrossRefGoogle ScholarPubMed
Leith, W. M., Lambert, W. E., Boehnlein, J. K., et al. (2019). The association between gabapentin and suicidality in bipolar patients. Int Clin Psychopharmacol, 34, 27–32.CrossRefGoogle ScholarPubMed
Berghöfer, A., Alda, M., Adli, M., et al. (2013). Stability of lithium treatment in bipolar disorder – long-term follow-up of 346 patients. Int J Bipolar Disord, 1, 11–18.CrossRefGoogle ScholarPubMed
Orsolini, L., Pompili, S. and Volpe, U. (2020). The “collateral side” of mood stabilizers: Safety and evidence-based strategies for managing side effects. Expert Opin Drug Saf, 19, 1461–1495.CrossRefGoogle Scholar